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INTRODUCTION
X-linked severe combined immunodeﬁciency (X-SCID)
is caused by mutations in the gene encoding the common
γ chain (γc), a shared signal transducing subunit of the inter-
leukin (IL)-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors
[1-10]. Defects in the γc account for approximately 50% of
cases of SCID and most cases of T–B+ SCID [11]. In
humans, the disease is characterized by low to absent
peripheral T-cells and natural killer (NK) cells and normal
or elevated levels of peripheral B-cells and by a marked
inability to mount effective cell-mediated and humoral
immune responses. If not successfully treated by bone mar-
row transplantation (BMT), X-SCID is fatal within the ﬁrst
2 years of life [12]. This severe phenotype of X-SCID can
be attributed to the pleiotropic effects of γc-containing
receptors on the development and maintenance of immune
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ABSTRACT
X-linked severe combined immunodeficiency (X-SCID) is the most common form of human SCID and is caused by
mutations in the common γ chain (γc), a shared component of the interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15, and
IL-21 receptors. BMT for human X-SCID results in engraftment of donor T-cells and reconstitution of normal
T-cell function but engraftment of few, if any, donor B-cells and poor reconstitution of humoral immune function.
Canine X-SCID is also caused by mutations in the γc and has an immunological phenotype identical to that of
human X-SCID. We have previously reported that transplantation of nonconditioned X-SCID dogs with unfraction-
ated histocompatible bone marrow results in engraftment of both donor B- and T-cells and reconstitution of normal
T-cell and humoral immune function. In this study, we assessed the ability of purified canine CD34+ bone marrow
cells to reconstitute lymphoid populations after histocompatible BMT in 6 nonablated X-SCID dogs. All dogs
showed engraftment of donor T-cells, with T-cell regeneration occurring through a thymic-dependent pathway, and
had reconstituted normal T-cell function. In contrast to our previous studies, only 3 dogs had engraftment of donor
B-cells and reconstituted normal antigen-specific B-cell function post-BMT. The variable donor B-cell engraftment
and reconstitution of normal humoral immune function observed in this study are similar to the outcomes observed
in the majority of human X-SCID patients following BMT. This study demonstrates that canine CD34+ cells con-
tain progenitors capable of immune reconstitution and is the first study to document the ability of CD34+ bone mar-
row cells to reconstitute normal B- and T-cell function in a nonablated large-animal model of BMT. This study also
demonstrates that the quality of immune reconstitution following CD34+ BMT may be dosage dependent. Thus
canine X-SCID provides a large-animal preclinical model that can be used not only to determine the optimal condi-
tions for both donor B- and T-cell engraftment following CD34+ BMT, but also to develop and evaluate strategies
for gene therapy protocols that target CD34+ cells.
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competence. Thymopoiesis requires IL-7; IL-15 and IL-21
are needed for generation and function of NK cells; IL-2 is
necessary for clonal expansion of mature T-lymphocytes
after activation; and IL-4 is required for B-lymphocyte
immunoglobulin class switching [10,13].
Since the ﬁrst BMT for X-SCID in 1968, advances in
BMT and T-cell–depletion techniques have allowed virtually
every X-SCID patient to be treated by either HLA-identical
or haploidentical BMT [14-16]. Despite the success of hap-
loidentical BMT for X-SCID, serious clinical complications
still exist, including failure of engraftment, Epstein-Barr
virus–associated lymphoproliferative disease, graft-versus-
host disease, and a failure to reconstitute normal humoral
immunity even after successful functional T-cell engraftment
[15-17]. The failure to reconstitute normal humoral immune
function has been observed after both haploidentical and
HLA-matched BMT and has been correlated most strongly
with a failure to engraft donor-derived B-cells [16-18].
Because of these problems, there is continuing impetus to
develop better and more effective protocols for treatment
of X-SCID using both conventional BMT and gene-transfer–
based protocols.
Successful treatment of X-SCID has also been achieved
using retrovirally mediated gene transfer to introduce a
normal copy of the γc gene into bone marrow progenitor
cells [19]. Because of the selective advantage that corrected
X-SCID T-lymphoid progenitors would have compared to
uncorrected cells, the ability to correct even 1 bone marrow
progenitor cell may have clinical benefit in patients with
X-SCID. Indeed, an X-SCID patient has been described in
whom a spontaneous reversion of a γc mutation in a single
T-cell precursor led to the production of a diverse T-cell
repertoire and partial amelioration of the X-SCID pheno-
type [20,21].
Mice rendered γc deﬁcient by homologous recombina-
tion and dogs with spontaneous canine X-SCID are 2 animal
models available for testing of either allogeneic BMT or
gene transfer for the treatment of X-SCID. The γc knockout
mice, unlike humans, have severe B- and T-lymphopenia that
is most likely due to the increased importance of IL-7 in
mouse B-cell lymphopoiesis [22-24]. Unlike the mouse
model, the canine model of X-SCID is homologous to the
human disease, with affected animals lacking mature T-cells
because of abnormal thymopoiesis but having phenotypic
B-cells with intrinsic defects in class switching [25-28].
Dogs with X-SCID typically succumb to overwhelming
infection within the ﬁrst 4 months of age if not successfully
treated. We have previously shown that the immune systems
of X-SCID dogs that have undergone transplantation with
normal unfractionated bone marrow cells reconstitute normal
B- and T-cell function [29,30]. Both mice and dogs have been
used to test γc gene transfer using human γc vectors [31-33].
CD34 is a 110-kD heavily glycosylated cell surface pro-
tein that is expressed on a subpopulation of bone marrow
cells that are capable of multilineage engraftment in pri-
mates and humans [34-36]. Recently the canine CD34 gene
was cloned, and a monoclonal antibody to the antigen was
produced [37,38]. Subsequently, transplantation of canine
CD34+ cells into irradiated hosts has led to radioprotective
reconstitution of the bone marrow compartment, suggest-
ing that CD34 is also a marker for dog bone marrow pro-
genitor cells [39]. To further evaluate the role of CD34+
cells in lymphohematopoietic development, we have used
the CD34+ population of normal canine bone marrow for
transplants in X-SCID dogs. The results indicate that
CD34+ canine marrow cells contain T- and B-lymphoid
progenitors capable of immune reconstitution after trans-
plantation into X-SCID dogs, with outcomes similar to
those observed after human clinical transplantation. These
experiments establish the X-SCID dog as a valuable model
for evaluating and enhancing both BMT and gene therapy
protocols for X-SCID.
MATERIALS AND METHODS
X-SCID Genotyping and Dog Leukocyte Antigen
Typing
X-SCID dogs were derived from a breeding colony
established from a carrier female that harbored a 4–base pair
(bp) deletion in the ﬁrst exon of the γc gene [27]. Diagnosis
of X-SCID pups employed a polymerase chain reaction
(PCR)–based mutation detection assay that was performed
at less than 1 week of age [27]. Inheritance of dog leukocyte
antigen (DLA) alleles within families was determined by a
PCR technique based on the inheritance of a microsatellite
locus within the class II region of the DLA and was used to
select matched healthy sibling donors [40]. Primer
sequences LUC2202 reverse 5′-TCTGTGGGAAGAG
GTAAGTTCA-3′ and LUC2202 forward 5′-CGTTCT
GCTCACATTTCGTTAT-3′ were used with 30 cycles of
PCR programs 94°C-1′, 62°C-1′, and 72°C-1′. Amplicons
were visualized on an 8% nondenaturing polyacrylamide
gel. The presence of matching bands was used to identify a
DLA-matched sibling donor for each affected X-SCID dog.
Transplantation in X-SCID Dogs
All experiments were performed in accordance with the
protocols approved by the University of Pennsylvania Insti-
tutional Animal Care and Use Committee (IACUC#
360600). Healthy DLA-matched donors were killed and
their bones obtained. The bones were cracked, scraped, and
ﬂushed with RPMI 1640 medium. The marrow was teased
apart and passed through a sterile 70-µm cell strainer (Bec-
ton Dickinson, Franklin Lakes, NJ). The resulting cell sus-
pension was centrifuged on a Ficoll-Hypaque 1.077 gradient
(Sigma, St Louis, MO) to remove red blood cells and then
washed twice with phosphate-buffered saline (PBS) contain-
ing 1% bovine serum albumin (BSA) and 100 U/mL DNaseI.
Cells were resuspended at a ﬁnal concentration of 1 × 108
cells/mL in a PBS solution containing 2 mmol/L EDTA,
0.1% BSA, and biotinylated anticanine CD34 antibody 1H6
at 40 µg/mL [39]. Cells were resuspended and then labeled
with the secondary antimouse immunoglobulin G (IgG)
MACS magnetic microbeads according to the manufactur-
er’s protocol (Miltenyi, Auburn, CA). Labeled cells were
selected on varioMACS columns as recommended by the
manufacturer. Aliquots of positively selected cells were
labeled with phycoerythrin (PE)-labeled streptavidin (Jack-
son Immunoresearch, West Grove, PA) and analyzed on a
FACScan ﬂow cytometer (Becton Dickinson, San Jose, CA)
to determine the purity of the eluted cells. X-SCID recipients
were intravenously catheterized and infused with irradiated
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(5400 cGy) CD34– cells 15 minutes prior to infusion of the
CD34+ selected cell population [41]. None of the dogs
received pretransplantation conditioning.
Monitoring of X-SCID Dogs after Transplantation
The X-SCID dogs that underwent transplantation were
monitored for evidence of engraftment at 4-week intervals.
Assays that were performed included proliferation assays,
complete blood cell count, ﬂow cytometric analysis of lym-
phocyte subsets, and determination of serum IgG levels. For
proliferation assays and flow cytometry, EDTA anticoagu-
lated blood was obtained and diluted 1:1 in Hanks’ balanced
salt solution (HBSS) without Ca++ or Mg++, layered over a
1.066 Ficoll-Hypaque gradient, and centrifuged at 400g for
20 minutes [42]. Peripheral blood mononuclear cells
(PBMCs) were subsequently washed twice in HBSS,
counted, and resuspended in RPMI 1640 supplemented
with 10% fetal calf serum.
Proliferation Assays
PBMCs were plated in triplicate at 105 cells per well in a
96-well microtiter plate (Costar, Corning, NY) and incu-
bated for 2 days at 37°C in a humidiﬁed 5% CO2 incubator
in triplicate with concentrations of phytohemagglutinin
(PHA-P) (Sigma) varying from 1 to 4 µg/mL. Tritiated
thymidine, 0.5 µCi (ICN, Costa Mesa, CA), was added to
cultures after 2 days, and cells were harvested on glass
microﬁber ﬁlters (Whatman, Maidstone, England) using an
automated cell harvester after 18 hours of additional incuba-
tion. Filter disks were removed, suspended in liquid scintil-
lation cocktail (Ecolume, ICN), and counted in a LS 6500
scintillation counter (Beckman Coulter, Fullerton, CA)
Flow Cytometry
Staining was performed on aliquots of 1 × 106 Ficoll
separated peripheral blood lymphocytes. PBMCs were
washed in PBS containing 1% BSA, centrifuged, resuspended
in PBS-BSA, and incubated for 20 minutes at 4°C with ﬂuo-
rescein isothiocyanate (FITC)-labeled antibodies to canine
surface Ig (Rockland, Gilbertsville, PA) or unlabeled mono-
clonal antibodies to canine CD3 (CA17.2A12), CD4 (LSM-
12.125), CD8 (LSM-4.78), CD21 (CA2.1D6), CD45RA
(CA4.1D3), and CD3-like (LSM-8.358). For indirect label-
ing, PBMCs were washed twice with PBS-BSA and incubated
with labeled secondary antibodies, FITC antimouse-speciﬁc
IgM, or PE-labeled antimouse IgG-specific antibodies
(Jackson Immunoresearch). Analysis of 10,000 events was
performed using a FACSCalibur flow cytometer (Becton
Dickinson). For cell sorting, PBMCs were stained with
FITC-labeled anticanine CD3 and PE-labeled anticanine
CD21. Cells were sorted by fluorescence into B-cell and
T-cell fractions using FACSVantage and FACStar flow
cytometers (Becton Dickinson).
Quantification of Serum IgG
Serum IgG was determined by radial immunodiffusion
using canine IgG-speciﬁc plates (Bethyl, Montgomery, TX).
Assessment of Antigen-Specific Antibody Response
After donor cells were detected in dogs that underwent
transplantation, the dogs were immunized intramuscularly
with 0.5 mL tetanus toxoid (Lederle, Pearl River, NY). Ani-
mals were reimmunized with tetanus toxoid 2 weeks after
the initial immunization. Serum samples were obtained
from the immunized animals at weekly intervals for 4 weeks
after the initial immunization. IgG-specific tetanus
toxoid–speciﬁc antibody was determined using an enzyme-
linked immunosorbent assay (ELISA). Ninety-six–well
ELISA plates (Costar) were coated overnight at 4°C with
200 µL of carbonate buffer (pH 9.6) containing 0.5 Lf
units/mL of tetanus toxoid (Wyeth-Ayerst Laboratories,
Marietta, PA). The plates were washed 3 times with
PBS–0.05% Tween 20 (PBS-T). Serial 2-fold serum dilu-
tions starting at 1:250 were made in buffer, and 200 mL was
added to the antigen-coated wells. All samples were tested in
duplicate. The plates were incubated at room temperature
for 2 hours and washed 3 times with PBS-T. Subsequently,
the plates were incubated for 2 hours at room temperature
with peroxidase-labeled antidog IgG (γ heavy chain speciﬁc,
Bethyl) diluted to 1:5000 in PBS-T. Plates were washed
3 times with PBS-T and then incubated for 20 minutes with
200 µL of o-phenylenediamine + 0.014% H2O2 substrate
solution (Sigma). The reaction was stopped by the addition
of 50 µL of 1N H2SO4 to each well. Absorbance at 490 nm
was measured by a microplate ELISA reader (Molecular
Devices, Menlo Park, CA). Endpoint titers were determined
by calculating the reaction of each test sample to the nega-
tive preimmunization sample. A ratio of >2.0 with an optical
density reading >0.2 was considered positive.
Chimerism Detection Assay
DNA was extracted from sorted cell populations (Gen-
tra Systems, Minneapolis, MN), and PCR was performed
using primers that flank the 4 bp of the γc gene that are
missing in affected X-SCID dogs. The 5′ primer was labeled
with 32P. Products from the PCR reaction were separated on
a standard 6% denaturing polyacrylamide sequencing gel by
electrophoresis at 2000 V for 7 hours. Gel data were cap-
tured using a GS525 storage phosphorimaging system
(BioRad, Hercules, CA) and analyzed using Multianalyst
software. Background counts were subtracted, and then the
data were normalized to the actual ratio of 32P in the larger
(169-bp normal) and smaller (165-bp mutant) PCR products
seen from the control carrier female. This procedure cor-
rects for any differences in PCR efﬁciency between the 165-
and 169-bp products. After the data were adjusted based on
the control carrier female (which was consistently between
47% and 53%), the percentage of donor cells was calculated
as the percentage of counts in the normal band compared to
the total counts in both bands. All data were within the
capacity of the phosphoimager to detect 32P in a linear
range. Consequently, the percentage of donor cells reported
is more accurate than the percentage calculated by visual
examination of the computer-generated gel image.
RESULTS
Bone Marrow Transplantation
Six dogs that were between 1 and 3 weeks of age
received CD34+ cell doses that ranged from 1.2 to 40.0 ×
106 cells/kg (Table). The purity of the CD34+ cells was
greater than 96% except in 1 recipient (R862).
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Normalization of Lymphocyte Subsets
During the ﬁrst 4 weeks of life, X-SCID dogs may have
absolute lymphocyte counts and B-cell numbers that are
normal, whereas T-cells have invariably been absent at the
time of BMT [25,26,29]. At 1 month post-BMT, R860, the
animal that received the highest dose of CD34+ cells, had
normal absolute lymphocyte numbers (Figure 1). The
remaining animals had abnormally low absolute lymphocyte
numbers at 1 month post-BMT. By 2 months post-BMT,
lymphocyte counts had normalized in all of the animals
except R775, the animal that received the lowest dose of
CD34+ cells. This dog continued to have marginal to sub-
normal lymphocyte counts throughout the study period of
6 months. Percentages of T-cells (Figure 2A) and absolute
numbers of T-cells (Figure 2B) were normalized in all the
animals except R775 at 2 months post-BMT. In R775, the
percentage of T-cells was not normalized until 3 months
after transplantation, and the absolute number of T-cells did
not reach normal levels within the study period. Percentages
of B-cells (Figure 2C) remained above normal in 4 of the
animals at 1 month after transplantation but had normalized
in all the animals but R862 by 2 months post-BMT.
Absolute numbers of B-cells were at or above normal in all
the animals throughout the study period (Figure 2D).
Reconstitution of T-Cell Function
Proliferation to PHA was used to assess the development
of mitogen-responsive T-cells (Figure 3). At 1 month post-
BMT, only 1 animal, R860, had normal lymphocyte prolifer-
ation. By 2 months post-BMT, all of the animals except
R775, the dog that received the lowest dose of CD34+ cells,
had normal responses to PHA. This dog did not attain nor-
mal levels of proliferation to PHA until 3 to 4 months after
transplantation. After normalization, proliferative responses
were stable throughout the remainder of the study.
The percentage of T-cells that were positive for the RA
isoform of CD45 was assessed to distinguish newly gener-
ated naïve T-lymphocytes from peripherally expanded T-cells
[43]. This assessment was important because over time
X-SCID dogs that do not receive transplants can develop
nonfunctional T-cells that express an activated CD45RO
phenotype [44]. By 2 months post-BMT, all animals except
R775 showed normal percentages of CD45RA+ T-cells (Fig-
ure 4). Additionally, sorted PBMC fractions from the dogs
that underwent transplantation showed that virtually all of
the T-cells present in these animals after 2 months of age
were donor derived. The development of donor-derived
T-cells was similar to that observed with unfractionated
bone marrow [29,30].
Reconstitution of B-Cell Function
The reconstitution of B-cell function in animals that
underwent transplantation was assessed by measuring serum
IgG levels, evaluating the IgG antibody response to tetanus
toxoid, and evaluating the percentage of engrafted donor
B-cells. IgG levels in these dogs showed a generally increas-
ing trend after transplantation in all of the animals except
R775 and R889 (Figure 5). The 4 dogs with increasing IgG
levels had reached normal levels by 6 months post-BMT.
High initial readings for IgG can be explained by the pres-
ence of maternally derived IgG.
In our previous transplantation studies using unfraction-
ated bone marrow, virtually all of the T-cells post-BMT
were of donor origin, whereas 30% to 50% of the total
peripheral B-cells were of donor origin. The engraftment of
donor B-cells in the recipients of CD34+ cells was assessed
using a similar PCR-based assay (Figure 6). Two of the
recipients had at least 15% donor B-cells. Two of the recipi-
ents had low levels (2%-4%) of donor B-cells, and 2 animals
had <2% donor B-cells.
Animals were also tested for their ability to produce a
speciﬁc IgG antibody response to a neoantigen, tetanus tox-
oid (Figure 7). The 2 animals that showed the highest level
Details of Infused Bone Marrow Cells
Total Cells, Total Cell Dose, CD34+ Cell Dose,
Animal Donor ×106* ×106 cells/kg CD34+, %† ×106 cells/kg
R743-M M 13.2 11.1 98.5 10.93
R775-M M 1.0 1.2 97.9 1.17
R860-M F 50.8 43.2 97.3 40.03
R862-M M 16.2 19.5 91.1 17.76
R868-F M 56.8 37.5 95.6 35.85
R889-M F 27.5 30.3 96.7 29.3
*Total nucleated cells.
†Lymphoid gate.
Figure 1. Lymphocyte counts in X-SCID dogs after BMT. Absolute
lymphocyte counts in X-SCID dogs were obtained at monthly intervals
after transplantation. Lymphocyte counts for normal dogs older than 1
month are greater than 3540 cells/mL.
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of donor B-cell engraftment, R860 and R743, also had near-
normal levels of antitetanus IgG. R862, R775, and R889 had
undetectable or low levels of detected donor B-cells and also
had correspondingly low tetanus toxoid IgG antibody
responses. One animal (R868) had low levels of donor B-cell
engraftment and a good tetanus toxoid response.
DISCUSSION
Previous studies have documented the ability of autolo-
gous and allogeneic DLA-identical canine CD34+ cells to
rescue lethally irradiated normal dogs with kinetics of neu-
trophil and platelet recovery similar to those observed using
unfractionated bone marrow [38,39]. This study extends
those observations by demonstrating that highly purified
DLA-identical canine CD34+ bone marrow cells are capable
of engrafting donor B- and T-cells in nonablated X-SCID
dogs. Although studies have shown that a population of
human CD34– cells also contains hematopoietic stem cell
activity, it is unlikely that CD34– cells contributed to the
immunologic reconstitution seen in the dogs that under-
went transplantation [45,46]. In one study, transplantation
of 107 autologous canine CD34– cells/kg failed to rescue
lethally irradiated normal adult dogs, with all 3 dogs dying
by 20 days posttransplantation [38].
The canine X-SCID transplantations described in this
study are most similar to those performed in human X-SCID
patients who undergo transplantation within the first few
months after birth. Two recent studies evaluating a large
cohort of SCID patients who underwent BMT showed that
young patient age at transplantation influences survival
outcome [16,47].
Figure 2. Percentage and absolute numbers of B- and T-cells in X-SCID dogs after BMT. The percentages of peripheral T-cells (A) and B-cells
(C) were determined through ﬂow cytometry. Absolute numbers of T-cells (B) and B-cells (D) were calculated using absolute lymphocyte counts.
Normal values for B-cell and T-cell percentages for dogs older than 1 month are 5% to 20% and 60% to 90%, respectively. Normal values for B-cell
and T-cell absolute numbers for dogs older than 1 month are 177 to 708 cells/mm3 and 2124 to 3186 cells/mm3, respectively.
Figure 3. Proliferative response of peripheral blood lymphocytes to
PHA in X-SCID dogs after BMT. Peripheral blood lymphocytes were
obtained from dogs at monthly intervals after transplantation and stim-
ulated with PHA. Normal proliferation values for animals older than
1 month are greater than 30,000 CPM.
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The kinetics of T-cell engraftment observed with our
CD34+ transplants were comparable to both those seen in
human X-SCID patients receiving transplants of T-cell–
depleted HLA-identical or haploidentical bone marrow cells
and those seen in our previous studies of canine X-SCID
using unfractionated bone marrow containing less than
1.5% mature T-cells. The proportions and absolute num-
bers of T-cells reached normal levels between 2 and
3 months posttransplantation in all but 1 dog, R775, which
received the lowest dose of CD34+ bone marrow cells. R775
remained T-lymphopenic throughout the study. It is
unlikely that any contaminating mature T-cells in the
CD34+ cell preparations contributed to the T-cell engraft-
ment in the dogs that underwent transplantation, because
the majority of the T-cells were naïve CD45RA+ lympho-
cytes consistent with their being recent thymic emigrants
[43,48]. It is likely that the majority of the CD3+ CD45RA+
cells observed post-BMT were CD4+ T-cells and were not
from extrathymic expansion of CD8+ T-cells [49], because
only 9.1% ± 3.1% of the T-cells in the animals were CD8+
at 2 months post-BMT (data not shown). The in vitro pro-
liferative response to T-cell mitogenic stimulation followed
similar kinetics, with normal responses observed between
2 and 3 months posttransplantation with the exception of
R775, in which the development of a normal proliferative
response was delayed.
The consistent development of donor-derived T-cells in
the nonmyeloablated X-SCID dogs is in contrast to the
results seen with B-cell engraftment. In the present study,
2 of 6 dogs developed signiﬁcant numbers of donor-derived
B-cells (>15% of total B-cells), whereas 2 of the dogs had
<2% donor B-cells. Both dogs with high levels of B-cell
engraftment produced normal levels of antigen-speciﬁc IgG
antibodies after immunization with tetanus toxoid. In con-
trast, the animals with low levels of B-cell engraftment gener-
ally had deﬁcient humoral function. These results differ from
those of our previous studies using unfractionated bone mar-
row, in which all X-SCID dogs that developed T-cell recon-
stitution also developed 20% to 50% donor-derived B-cells
and normal levels of antigen-speciﬁc IgG antibody [29,30].
Although this study was not designed to test the effect
of CD34 cell dose, it appears that cell dose does inﬂuence
the quality of T-cell reconstitution. The dog that received
the lowest dose of cells, 1 × 106 CD34+ cells/kg, exhibited a
delayed T-cell reconstitution with the absolute number of
T-cells never reaching normal values and an inability to pro-
duce IgG-specific antibody. In contrast, all dogs that
received >10 × 106 CD34+ cells/kg exhibited normal T-cell
reconstitution based on the parameters examined. Although
it is clear that the dose of CD34+ cells appears to inﬂuence
T-cell reconstitution, the effect of cell dose on reconstitu-
tion of normal humoral immune function is less clear. In
general, the dogs that received the higher doses of CD34+
bone marrow cells appeared to be better able to produce
IgG-specific antibody following immunization. Previous
studies have also reported an association between CD34+
cell dose and rate of engraftment, with dogs receiving less
than 106 CD34+ cells/kg exhibiting delayed neutrophil
recovery and a markedly delayed platelet recovery [39].
The development of donor-derived T-cells but variable
engraftment of donor B-cells in the present study is similar
to the outcomes observed in published reports of HLA-
identical and T-cell–depleted haploidentical BMTs in
human X-SCID patients. All human patients with successful
transplantation show engraftment of donor T-cells and
attain normal T-cell function, but few patients have engraft-
ment of donor B-cells, with the majority having continual
humoral immune deficiencies that require many of these
patients to be maintained on intravenous immune globulin
(IVIG) therapy [16,17]. The presence of low levels of IgG
antibody in canine and X-SCID patients who have not had
engraftment of donor B-cells after BMT may be due to a
γc-independent IL-4 signaling pathway [50,51]. However,
recent reports have suggested that normal effective humoral
immunity in human X-SCID patients who undergo BMT
can only be achieved by the engraftment of donor B-cells,
even at low levels [17,18]. Together, these ﬁndings indicate
Figure 5. Serum IgG concentrations in X-SCID dogs at indicated
time points following BMT. Normal serum IgG concentration for
6-month-old healthy dogs is 1028 mg/dL ± 312 mg/dL.
Figure 4. Proportion of CD45RA+ T-cells in X-SCID dogs at indi-
cated time points after BMT. Peripheral blood lymphocytes were
obtained from X-SCID dogs at monthly intervals and analyzed through
flow cytometry to determine the percentage of CD3+ T-cells that
expressed the RA isoform of CD45. Normal percentages for animals
1 through 6 months of age is greater than 85% CD45RA+ CD3+ T-cells.
B. J. Hartnett et al.
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that the best way to attain functional humoral immunity fol-
lowing BMT is to ensure the engraftment of significant
numbers of normal donor B-cells.
The failure of many transplantation-treated X-SCID
patients to show engraftment of significant numbers of
donor B-cells suggests that much of the observed T-cell
reconstitution is derived from either a small number of γc
normal stem cells or committed lymphoid progenitors [52].
This derivation is possible because there is a selective advan-
tage for a normal γc in lymphoid progenitors committed to
the T-cell lineage. This developmental selective advantage
does not apply to cells of the B- or myeloid lineage in
humans or dogs. Therefore, the number of circulating γc+
B-cells and myeloid cells is an indicator of the extent of
engraftment of true donor or gene-corrected progenitor
cells. High levels of such engraftment should be a major
goal for any BMT or gene therapy approach to treatment of
X-SCID, not only to ensure normal B-cell function and
obviate the need for IVIG treatment, but also to ensure
durable T-cell function, especially considering that the pro-
duction of thymically derived T-cells appears to occur
throughout adult life [53,54].
One method of achieving this result could be the use of
pretransplantation conditioning. Nonmyeloablative condi-
tioning of recipients using busulfan (8 mg/kg) and cyclo-
phosphamide (200 mg/kg) has recently been reported not to
influence donor B-cell engraftment following BMT of
human X-SCID patients; however, true myeloablative ther-
apy could potentially improve the likelihood of donor B-cell
engraftment [17]. Although true cytoablative therapy prior
to transplantation may improve the likelihood of donor
B-cell engraftment, elucidation of the conditions allowing
full immunologic reconstitution and engraftment of both
donor B- and T-cells in X-SCID dogs receiving transplants
without pretransplantation conditioning needs to be
explored because cytoablation increases the risk of life-
threatening infections during the posttransplantation period
and requires lengthy hospitalization, thus increasing the cost
of BMT. In addition, long-term sequelae, including growth
retardation, sterility, learning disabilities, and possible
malignancies, have to be considered following the use of
pretransplantation cytoablation [55,56]. Pretransplantation
conditioning may also have an adverse effect on the bone
marrow, and possibly thymic, microenvironments, which
would influence the outcome of the BMT [57-59]. In the
absence of such a conditioning regimen, the engraftment of
transplanted cells can essentially be viewed as a competitive
repopulation in which the number of normal cells that are
Figure 6. PCR analysis of peripheral blood B-cells in X-SCID dogs after BMT. Peripheral blood B-cells were ﬂow sorted from X-SCID dogs that
underwent transplantation. Shown are the products of a PCR reaction that ampliﬁes a region spanning the 4-bp deletion that occurs in our colony.
The upper band represents the 169-bp normal PCR fragment, and the lower band represents the 165-bp mutant fragment. The percentage of total
counts that were acquired in the normal band is expressed above each lane. Carrier indicates heterozygous female.
Figure 7. IgG-speciﬁc antibody responses to tetanus toxoid in X-SCID dogs after BMT. Serum samples were obtained prior to immunization and
at weekly intervals following primary and secondary immunization (↑). An ELISA speciﬁc for tetanus toxoid was performed using 2-fold dilutions of
serum starting at 1:250. Results of the dogs that underwent transplantation are compared with pooled sera from immunized healthy dogs.
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infused is correlated with the amount of donor cell
chimerism seen in the periphery [60]. Therefore, maximiz-
ing the number of normal cells that are infused, whether
from healthy donors or transduced autologous cells, is of
great importance.
Donor B-cell engraftment was observed in our previous
studies of transplantation of unfractionated bone marrow in
X-SCID dogs [29,30] as well as in some of the recipients in
the present study in which CD34+ donor cells were used. In
human X-SCID patients who receive transplants of either
unfractionated marrow or T-cell–depleted marrow without
myeloablative conditioning, donor B-cell engraftment is
rarely observed [16,17]. The higher frequency of donor B-cell
engraftment in the X-SCID dogs may reflect either the
larger number of CD34+ progenitor cells transplanted in the
canine experiments or the increased B-cell progenitor con-
tent of the canine CD34+ cells from young puppies. We
have observed that approximately 14% of the nucleated
marrow cells from 2- to 3-week-old puppies are CD34+ cells
(Suter et al., unpublished data). As a result, the recipients of
unfractionated marrow received estimated doses of CD34+
cells as high as 20 × 106 cells/kg. Similar high cell doses
were given to most of the recipients of puriﬁed CD34+ cells
in the present study. These doses of CD34+ cells are signiﬁ-
cantly higher than those used in human histocompatible or
haploidentical BMT and may contribute to the higher fre-
quency of B-cell engraftment observed in the dogs. Addi-
tionally, the CD34+ cells from very young dogs may have a
higher frequency of B-lymphoid progenitors. Data from
transplantation of human CD34+ cells into immunodeﬁcient
mice or patients have suggested greater B-lymphoid poten-
tial from umbilical cord blood cells [61-64]. It is possible
that the CD34+ cells from the very young puppies used as
donors in the present experiments are similar to umbilical
cord blood cells in that they have a high potential for B-cell
engraftment and generation. Thus, the canine experiments
suggest several strategies to increase B-cell engraftment
after nonmyeloablative transplantation, notably the use of
high cell doses and very young donors.
Historically, the dog has been a valuable model for
BMT, with many of the advances achieved in the dog being
directly transferable to human clinical BMT protocols
[65,66]. In canine X-SCID, unlike mouse γc-deﬁciency, the
role of the γc in lymphoid development and function is simi-
lar to humans, allowing canine X-SCID to serve as a unique
large-animal preclinical model to determine the optimal
conditions for both donor B- and T-cell engraftment fol-
lowing allogeneic CD34+ BMT. Determination of the opti-
mal conditions for engraftment of CD34+ cells will also be
directly applicable to gene therapy studies because CD34+
cells are currently the target for transduction protocols.
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